Search research articles
Contact Us
Filters
Showing results (51-60 of 78) with videos related to
Page
of 8
Sort By:
European Urology
|
July 12, 2021
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer
Stéphane Supiot, Loig Vaugier, David Pasquier, et al.
The Lancet. Oncology
|
October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
Paul Sargos, Sylvie Chabaud, Igor Latorzeff, et al.
BMC Cancer
|
July 2, 2025
Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer
Martin Boegemann, Mostefa Bennamoun, Louis Marie Dourthe, et al.
European Urology Oncology
|
November 8, 2025
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial
Thomas Zilli, Dirk Böhmer, Andreas Roeder, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 18, 2018
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)
Loig Vaugier, Clément Palpacuer, Emmanuel Rio, et al.
Radiation Oncology (London, England)
|
April 9, 2016
Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study
Sophie Jacob, Atul Pathak, Denis Franck, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 12, 2021
Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder
Jonathan Khalifa, Stéphane Supiot, Géraldine Pignot, et al.
European Urology
|
November 28, 2015
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Gwenaelle Gravis, Jean-Marie Boher, Florence Joly, et al.
Lancet (London, England)
|
October 1, 2020
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Claire L Vale, David Fisher, Andrew Kneebone, et al.
European Urology Oncology
|
January 4, 2026
Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer
François Rozet, Alain Ruffion, Pablo Lemercier, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 78) with videos related to
Sort By:
Page
of 8
European Urology
|
July 12, 2021
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer
Stéphane Supiot, Loig Vaugier, David Pasquier, et al.
The Lancet. Oncology
|
October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
Paul Sargos, Sylvie Chabaud, Igor Latorzeff, et al.
BMC Cancer
|
July 2, 2025
Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer
Martin Boegemann, Mostefa Bennamoun, Louis Marie Dourthe, et al.
European Urology Oncology
|
November 8, 2025
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial
Thomas Zilli, Dirk Böhmer, Andreas Roeder, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 18, 2018
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)
Loig Vaugier, Clément Palpacuer, Emmanuel Rio, et al.
Radiation Oncology (London, England)
|
April 9, 2016
Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study
Sophie Jacob, Atul Pathak, Denis Franck, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 12, 2021
Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder
Jonathan Khalifa, Stéphane Supiot, Géraldine Pignot, et al.
European Urology
|
November 28, 2015
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Gwenaelle Gravis, Jean-Marie Boher, Florence Joly, et al.
Lancet (London, England)
|
October 1, 2020
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Claire L Vale, David Fisher, Andrew Kneebone, et al.
European Urology Oncology
|
January 4, 2026
Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer
François Rozet, Alain Ruffion, Pablo Lemercier, et al.
Page
of 8